细菌溶解产物泛福舒治疗婴幼儿毛细支气管炎继发支气管哮喘的临床效果和免疫机制研究
2016/07/27
摘要
目的：旨在研究细菌溶解产物（泛福舒OM-85BV）治疗婴幼儿毛细支气管炎继发支气管哮喘的临床效果和免疫机制。
患者和方法：选择了2013年2月至2014年2月间136例婴幼儿毛细支气管炎继发支气管哮喘病例。本研究经我院伦理委员会批准，并获得患者及监护人的知情同意权。患者分为对照组（n = 62）和观察组（n = 74），采用随机数表法。对照组患者用正常糖皮质激素雾化吸入、氨茶碱和抗生素治疗。观察组除了上述治疗之外，我们增加了泛福舒OM-85BV，一天一次口服给药连续治疗10天，然后停止治疗20天。治疗总共持续了3个月。随访约一年，以比较效果。
结果：观察组毛细支气管炎和哮喘发作的频率和持续时间明显下降，与对照组比较差异显著（P＜0.05）。观察组中IL-17和IL-4水平明显降低，而IL-10和IFN-γ水平大大增加。差异均显著（P＜0.05）。与对照组比较，外周血CD4 + T淋巴细胞在观察组患者中表达较低水平的α7烟碱型乙酰胆碱受体（α7nAChR），该差异显著（P＜0.05）。
结论：泛福舒OM-85BV降低婴幼儿毛细支气管炎继发支气管哮喘的发作，与减少炎症反应有关。它也调节Th1/Th2免疫功能，并降低α7nAChR水平。
（苏欣 审校）
Eur Rev Med Pharmacol Sci. 2016 May;20(10):2151-5.
Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthmatreated with bacterial lysates Broncho-Vaxom.
Han RF1, Li HY, Wang JW, Cong XJ.
Author information
Abstract
OBJECTIVE:To study the clinical effects and immunologic mechanism of infant capillary bronchitis secondary bronchial asthma treated with bacterial lysates (Broncho-Vaxom OM-85BV).
PATIENTS AND METHODS:Between February 2013 and February 2014, 136 infant capillary bronchitis secondary bronchial asthma cases were chosen. This research was approved by Ethics Committee in our hospital and obtained the informed consent right from patients and guardians. Patients were divided into the control group (n = 62) and the observation group (n = 74) using random number table method. Patients in the control group were treated with normal glucocorticoid atomizing inhalation, aminophylline and antibiotic treatment. In the observation group besides the abovementioned treatment, we added Broncho-Vaxom OM-85BV, qd po for 10 days continuously and quitted it for 20 days. This continued for a total of 3 months. Follow-ups were set for about one year to compare the effects.
RESULTS:The onset frequency and duration of capillary bronchitis and asthma in observation group declined remarkably compared with control group and the differences were statistically significant (p < 0.05). The level of IL-17 and IL-4 in the observation group decreased significantly, whereas, the level of IL-10 and IFN- γ increased considerably. Differences were all statistically significant (p < 0.05). Peripheral blood CD4+ T lymphocytes in the observation group patients expressed lower levels of nicotinic acetylcholine receptors α7 (α7nAChR) compared to the control group. Then difference was statistically significant (p < 0.05).
CONCLUSIONS:Broncho-Vaxom OM-85BV reduced the onset of infant capillary bronchitis secondary bronchial asthma, relating to the reduced inflammation reaction. It also regulated the immunologic function of Th1/Th2, and lowered the α7nAChR level.
Eur Rev Med Pharmacol Sci. 2016 May;20(10):2151-5.
上一篇：
在草花粉过敏的儿童中用单磷酰脂质A佐剂特异性免疫治疗一个周期后支气管耐受性的诱导
下一篇：
对重症未控制的哮喘患者住院和门诊使用奥马珠单抗的成本和临床疗效之间的比较
